ArticleAnalytica chimica acta2007
An immunoaffinity tandem mass spectrometry (iMALDI) assay for detection of Francisella tularensis.
Article in Analytica chimica acta, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Natural and synthetic polymer-based smart biomaterials for management of ulcerative colitis: a review of recent developments and future prospects.Drug delivery and translational research · 2019Review
- Peptide and Protein Quantification Using Automated Immuno-MALDI (iMALDI).Journal of visualized experiments : JoVE · 2017Article
- Analytical validation considerations of multiplex mass-spectrometry-based proteomic platforms for measuring protein biomarkers.Journal of proteome research · 2014Review
- Mass spectrometry based biomarker discovery, verification, and validation--quality assurance and control of protein biomarker assays.Molecular oncology · 2014Review
- Development and evaluation of an immuno-MALDI (iMALDI) assay for angiotensin I and the diagnosis of secondary hypertension.Clinical proteomics · 2013Article
- Efficient sample preparation in immuno-matrix-assisted laser desorption/ionization mass spectrometry using acoustic trapping.Biomicrofluidics · 2013Article
- Evaluation of protein quantification using standard peptides containing single conservative amino acid replacements.Journal of mass spectrometry : JMS · 2012Article
- Non-Biased Enrichment Does Not Improve Quantitative Proteomic Delineation of Reovirus T3D-Infected HeLa Cell Protein Alterations.Frontiers in microbiology · 2012Article
- Revealing plant defense signaling: getting more sophisticated with phosphoproteomics.Plant signaling & behavior · 2011Review
- Peptide immunoaffinity enrichment coupled with mass spectrometry for peptide and protein quantification.Clinics in laboratory medicine · 2011Review
- The path to clinical proteomics research: integration of proteomics, genomics, clinical laboratory and regulatory science.The Korean journal of laboratory medicine · 2011Review
- MALDI immunoscreening (MiSCREEN): a method for selection of anti-peptide monoclonal antibodies for use in immunoproteomics.Journal of immunological methods · 2011Article
- Reconstructing the pipeline by introducing multiplexed multiple reaction monitoring mass spectrometry for cancer biomarker verification: an NCI-CPTC initiative perspective.Proteomics. Clinical applications · 2010Review
- A quantitative study of the effects of chaotropic agents, surfactants, and solvents on the digestion efficiency of human plasma proteins by trypsin.Journal of proteome research · 2010Article
- Towards the development of an immuno MALDI (iMALDI) mass spectrometry assay for the diagnosis of hypertension.Journal of the American Society for Mass Spectrometry · 2010Article
- Mass-spectrometry-based clinical proteomics--a review and prospective.The Analyst · 2010Review
- Article
- Killing of trypanosomatid parasites by a modified bovine host defense peptide, BMAP-18.PLoS neglected tropical diseases · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Francisella tularensis (F. tularensis) has been designated by the CDC as 1 of the 10 organisms most likely to be engineered for bioterrorism. Symptoms of tularemia in humans are non-specific, thus making the disease difficult to diagnose. If not quickly diagnosed and treated, the disease has a high mortality rate--thus methods for early and specific diagnosis are of critical importance. This immunoaffinity MALDI MS/MS (iMALDI) assay provides unambiguous detection of F. tularensis peptides at attomole levels from peptide solutions, and at low CFU levels from bacteria. The addition of stable-labeled versions of the peptide as internal standards allows absolute quantitation of F. tularensis peptides with a linear dynamic range spanning two orders of magnitude. The ability of mass spectrometry to obtain amino acid sequence data on affinity-captured peptides provides absolute specificity and avoids "false positives" from the non-specific binding. The F. tularensis iMALDI assay has been applied to different samples, such as nasal swabs. This novel quantitative diagnostic F. tularensis iMALDI assay allows the safe, sensitive, and specific detection of F. tularensis. The assay can be easily adapted to other target peptides and therefore has broad application potential in clinical diagnosis of other pathogens and diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.